Merck KGaA Entered into a Collaboration with Hengrui to Strengthen its Oncology Pipeline for Next-Generation Selective PARP1 Inhibitor and Antibody Drug Conjugate

Published: October 2023

On 30 October 2023, Merck KGaA entered into an agreement with Hengrui with an aim to develop and commercialize next-generation selective PARP1 inhibitor HRS-1167 and Claudin18.2 antibody-drug conjugate SHR-A1904. The company aims to utilize Hengrui’s internal DNA damage response expertise and in-house ADC capabilities.

Additionally, Merck KGaA aims to provide Hengrui with an upfront payment of €160 million which will be utilized in development, regulatory and commercial milestones. Potential payments are estimated to reach over €1.4 billion.

According to Roots Analysis, the Antibody Drug Conjugates Market is estimated to be worth $7.72 billion in 2023 and is expected to grow at a CAGR of 9.6% during the forecast period.

For detailed insights about this domain, check out our report on Antibody Drug Conjugates Market or email


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry